MedTrace Logo

Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects

NCT06198556 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-02-28

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy adult subjects after oral administration of HRS-1167 tablets. The secondary objective of the study is to evaluate the safety of HRS-1167 alone and when co-administered with rifampicin.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

HRS-1167 tablets; rifampicin

HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-14
Primary Completion
2024-02-05
Completion
2024-02-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06198556 on ClinicalTrials.gov